$KRYS
Krystal Biotech, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018011136 Filed on May 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $920.0K $760.0K $150.0K
YoY Change 240.74% 406.67%
% of Gross Profit
Research & Development $1.525M $1.520M $319.0K
YoY Change 241.93% 376.49%
% of Gross Profit
Depreciation & Amortization $23.00K $18.00K $1.000K
YoY Change 666.67% 1700.0%
% of Gross Profit
Operating Expenses $2.449M $2.277M $465.0K
YoY Change 242.52% 389.68%
Operating Profit -$2.449M -$2.277M -$465.0K
YoY Change 242.52% 389.68%
Interest Expense $170.0K $130.0K -$30.00K
YoY Change -525.0% -533.33%
% of Operating Profit
Other Income/Expense, Net $173.0K $127.0K -$29.00K
YoY Change -493.18% -537.93%
Pretax Income -$2.280M -$2.150M -$490.0K
YoY Change 200.0% 338.78%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.276M -$2.150M -$494.0K
YoY Change 199.87% 335.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$221.1K -$208.5K -$56.45K
COMMON SHARES
Basic Shares Outstanding 10.31M 10.31M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.50M $47.20M $2.000M
YoY Change 1200.0% 2260.0%
Cash & Equivalents $41.81M $47.23M $1.923M
Short-Term Investments $3.600M
Other Short-Term Assets $300.0K $400.0K $200.0K
YoY Change -25.0% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $45.70M $47.67M $2.100M
YoY Change 1071.79% 2169.95%
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K $182.0K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $64.00K
YoY Change
Total Long-Term Assets $330.0K $182.0K $100.0K
YoY Change 230.0% 82.0%
TOTAL ASSETS
Total Short-Term Assets $45.70M $47.67M $2.100M
Total Long-Term Assets $330.0K $182.0K $100.0K
Total Assets $46.03M $47.85M $2.200M
YoY Change 1050.75% 2075.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $214.0K $89.00K $100.0K
YoY Change -28.67% -11.0%
Accrued Expenses $500.0K $300.0K $0.00
YoY Change 25.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $759.0K $452.0K $100.0K
YoY Change -84.19% 352.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.100M
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $2.100M
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $759.0K $452.0K $100.0K
Total Long-Term Liabilities $0.00 $0.00 $2.100M
Total Liabilities $759.0K $452.0K $2.300M
YoY Change -84.19% -80.35%
SHAREHOLDERS EQUITY
Retained Earnings -$13.50M -$11.22M
YoY Change
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $45.27M $47.40M -$100.0K
YoY Change
Total Liabilities & Shareholders Equity $46.03M $47.85M $2.200M
YoY Change 1050.75% 2075.05%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.276M -$2.150M -$494.0K
YoY Change 199.87% 335.22%
Depreciation, Depletion And Amortization $23.00K $18.00K $1.000K
YoY Change 666.67% 1700.0%
Cash From Operating Activities -$1.620M -$2.369M -$260.0K
YoY Change 295.12% 811.15%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K $0.00 $7.000K
YoY Change 233.33% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$3.700M
YoY Change
Cash From Investing Activities -$3.800M $0.00 -$10.00K
YoY Change 12566.67% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.000K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 6.000K 300.0K
YoY Change -100.0% -98.0% 200.0%
NET CHANGE
Cash From Operating Activities -1.620M -2.369M -260.0K
Cash From Investing Activities -3.800M 0.000 -10.00K
Cash From Financing Activities 0.000 6.000K 300.0K
Net Change In Cash -5.420M -2.363M 30.00K
YoY Change -447.44% -7976.67% -70.0%
FREE CASH FLOW
Cash From Operating Activities -$1.620M -$2.369M -$260.0K
Capital Expenditures -$100.0K $0.00 $7.000K
Free Cash Flow -$1.520M -$2.369M -$267.0K
YoY Change 300.0% 787.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10309615
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
323000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
49914000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
200000
CY2018Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
363000
CY2018Q1 us-gaap Assets
Assets
47851000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
182000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47228000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49591000
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
441000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
47669000
CY2017Q4 us-gaap Assets
Assets
50114000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
89000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
193000
CY2017Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
447000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
452000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
640000
CY2018Q1 us-gaap Liabilities
Liabilities
452000
CY2017Q4 us-gaap Liabilities
Liabilities
640000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10307247
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1520000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
319000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58619000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58544000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11220000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9070000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
47399000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
49474000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47851000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50114000
CY2018Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2018Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
20000000
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
20000000
CY2018Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
2061773
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
2061773
CY2018Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10309615
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10307247
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10309615
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-7000
CY2017Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
300000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
300000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2363000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
36000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1923000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1959000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
757000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
146000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2277000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
465000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2277000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-465000
CY2018Q1 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
127000
CY2017Q1 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
-29000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
127000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-29000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-2150000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-494000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2150000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-494000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10307379
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3490884
CY2018Q1 us-gaap Depreciation
Depreciation
18000
CY2017Q1 us-gaap Depreciation
Depreciation
1000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
65000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
91000
CY2017Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
30000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
118000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-73000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-104000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
16000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-80000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
26000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2369000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-257000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2017Q1 krys Conversion Of Preferred Units To Preferred Stock
ConversionOfPreferredUnitsToPreferredStock
1306000
CY2018Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
1000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.86%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: stock-based compensation expense, accrued research and development expenses, the fair value of financial instruments, and the valuation allowance included in the deferred income taxes calculations.</p></div>
CY2018Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</p> <p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.86%;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents. The Company&#8217;s policy is to invest its cash and cash equivalents in money market funds and various bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</p></div>
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
77000
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q1 krys Stock Conversion Rate
StockConversionRate
1.0
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
233464
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
161055
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
225000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
225000
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25000
CY2018Q1 krys Accrued Pre Clinical Expenses
AccruedPreClinicalExpenses
100000
CY2017Q4 krys Accrued Pre Clinical Expenses
AccruedPreClinicalExpenses
257000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
129000
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
900000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
185332
CY2018Q1 krys Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted
55000
CY2018Q1 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
84000
CY2017Q4 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
10000
CY2018Q1 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
50000
CY2017Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
103000
CY2018Q1 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
363000
CY2017Q4 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
447000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
63000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
63000
CY2018Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
31000
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
19000
CY2017Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.22222222
CY2018Q1 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
1-to-4.5
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.00001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2017Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
20000000
CY2017Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4142000
CY2017Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
112000
CY2017Q3 us-gaap Long Term Debt
LongTermDebt
4254000
CY2017Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-3159000
CY2018Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of shares of common stock are entitled to one vote for each share of common stock held
CY2018Q1 us-gaap Dividends Common Stock Stock
DividendsCommonStockStock
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
55000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2018Q1 krys Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised
0
CY2018Q1 krys Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledOrForfeited
4500
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
849500
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2368
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
4500
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
233464
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
35523
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
35523
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.91
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.85
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.46
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.00
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.21
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.46
CY2018Q1 krys Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
2.46
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M17D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M17D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1224000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1157000
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
271000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
271000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
18000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
65000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000

Files In Submission

Name View Source Status
0001564590-18-011136-index-headers.html Edgar Link pending
0001564590-18-011136-index.html Edgar Link pending
0001564590-18-011136.txt Edgar Link pending
0001564590-18-011136-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
krys-10q_20180331.htm Edgar Link pending
krys-20180331.xml Edgar Link completed
krys-20180331.xsd Edgar Link pending
krys-20180331_cal.xml Edgar Link unprocessable
krys-20180331_def.xml Edgar Link unprocessable
krys-20180331_lab.xml Edgar Link unprocessable
krys-20180331_pre.xml Edgar Link unprocessable
krys-ex311_84.htm Edgar Link pending
krys-ex312_83.htm Edgar Link pending
krys-ex321_85.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending